A novel microRNA signature predicts survival in liver hepatocellular carcinoma after hepatectomy

Qiang Fu, Fan Yang, Tengxiao Xiang, Guoli Huai, Xingxing Yang, Liang Wei, Hongji Yang, Shaoping DengScientific 2018 · DOI

TL;DR

Researchers have identified a novel seven-microRNA (miRNA) signature that can predict overall survival in patients with liver hepatocellular carcinoma (LIHC) after surgery. This signature holds promise as a prognostic biomarker to guide therapy and potentially improve patient outcomes, especially in early-stage disease.

What Problem Does This Paper Address?

Liver hepatocellular carcinoma (LIHC) is a major global health concern, being the most common type of primary liver cancer. While treatments like surgical resection, liver transplantation, and ablation can offer temporary improvements, the overall survival (OS) rates for LIHC patients remain poor. Current prognostic tools, such as TNM staging and pathological grading, have limitations in accurately predicting outcomes due to challenges in staging and grading. This necessitates the identification of more specific and reliable prognostic markers to guide treatment decisions and improve patient survival. MicroRNAs (miRNAs), small non-coding RNA molecules that regulate gene expression, have emerged as potential biomarkers due to their stability and involvement in various cellular processes, including cancer development and progression.

Methods

The study employed a multi-faceted bioinformatics approach to identify and validate a miRNA signature for LIHC prognosis.

  • Data Acquisition and Preprocessing: Genome-wide miRNA-Seq and mRNA expression profiles, along with clinical data, were obtained from The Cancer Genome Atlas (TCGA) database. Patients with less than 30 days of follow-up were excluded to avoid bias from unrelated deaths.
  • Identification of Differentially Expressed miRNAs: Raw miRNA counts from paired primary tumor and normal tissues were analyzed to identify miRNAs that were significantly dysregulated in LIHC. A stringent FDR-adjusted p-value and log fold change cutoff were used.
  • Prognostic miRNA Identification: A semi-supervised method and univariate Cox regression analysis were used to identify miRNAs associated with overall survival (OS) within different clinical subgroups.
  • Prognostic Risk Model Development: A linear prognostic model was constructed using a semi-supervised principal components (SPC) method to select significant miRNAs. This model generated a prognostic score for each patient.
  • Model Validation: The TCGA dataset was randomly divided into training and testing sets for model development and validation. Kaplan-Meier analysis and time-dependent Receiver Operating Characteristic (ROC) curves were used to evaluate the predictive power of the seven-miRNA signature for 5-year survival.
  • Independent Prognostic Factor Assessment: Cox multivariate regression analysis was performed to determine if the seven-miRNA signature was an independent prognostic factor, independent of other clinical variables.
  • In Silico Target Gene and Pathway Analysis: Predicted target genes of the identified miRNAs were analyzed using databases like miRecords, and functional enrichment analysis was conducted using DAVID and KEGG to understand the biological pathways involved.

Datasets

  • The Cancer Genome Atlas (TCGA): This was the primary dataset used, providing miRNA expression profiles (level 3), mRNA expression profiles, and clinical data for 318 LIHC patients. Paired primary tumor and solid tumor normal tissue samples were also utilized for differential expression analysis.

Key Insights and Ideas

  • A Seven-miRNA Signature for Prognosis: The study successfully identified a specific signature composed of seven miRNAs that can predict overall survival in LIHC patients. This is a significant step towards more personalized medicine for this cancer.
  • Early Stage Predictivity: The identified signature demonstrated strong predictive power not only for the entire LIHC cohort but also specifically for patients in early stages (Stage I and II). This is crucial as early intervention can significantly impact outcomes.
  • Independent Prognostic Factor: The seven-miRNA signature was confirmed as an independent prognostic factor, meaning its predictive ability is not confounded by common clinical variables like age, grade, or TNM stage. This strengthens its potential as a reliable biomarker.
  • Therapeutic Target Potential: Beyond being a biomarker, the study suggests that this miRNA signature could also serve as a therapeutic target itself, opening avenues for novel treatment strategies.
  • miRNA Roles in LIHC: The discussion highlights the complex roles of individual miRNAs within the signature, with some acting as risk factors (e.g., miR-187, miR-9-3) and one as a protective factor (miR-3144), underscoring the intricate regulatory networks in LIHC.

Key Results

  • Differentially Expressed miRNAs: 156 miRNAs were found to be differentially expressed between LIHC tumors and normal tissues, with 37 upregulated and 119 downregulated.
  • Seven-miRNA Signature: A linear prognostic model incorporating seven specific miRNAs (miR-187, miR-9-3, miR-490, miR-1258, miR-3144, miR-551a, and miR-665) was established.
  • Survival Prediction: The seven-miRNA signature significantly correlated with overall survival. In the training set, high-risk patients had poorer outcomes (P < 0.001). In the entire LIHC cohort, the signature also showed significant predictive power (P = 0.0015).
  • ROC Curve Performance: Time-dependent ROC curve analysis showed an AUC of 0.703 for the training set and 0.645 for the entire cohort, indicating good predictive accuracy. For early-stage patients, the AUC was 0.652.
  • Independent Prognostic Factor: Cox multivariate regression analysis confirmed the seven-miRNA signature as an independent prognostic factor (HR = 1.034, P = 0.007).

Limitations and Future Work

  • Prospective Validation Needed: The authors acknowledge that while the study provides strong evidence, prospective, large-scale, multicenter studies are still required for further validation before the results can be fully applied in clinical settings.
  • In Silico Analysis Limitations: The target gene and pathway analyses were performed in silico. While informative, these predictions require experimental validation to confirm direct interactions and functional consequences.
  • Discrepancies in miRNA Roles: The study notes discrepancies in the reported roles of certain miRNAs (e.g., miR-9-3) across different studies, suggesting that subtle variations in patient populations, race, or experimental conditions might influence these findings. Further research is needed to clarify these inconsistencies.
  • Further Validation of Specific miRNAs: While the signature as a whole is validated, the authors suggest that further work is needed to validate the prognostic and target roles of individual miRNAs, particularly miR-3144, for clinical applications.

Summary updated

Abstract

Liver hepatocellular carcinoma (LIHC) is the most common type of primary liver cancer. In the current study, genome-wide miRNA-Seq and mRNA profiles in 318 LIHC patients derived from The Cancer Genome Atlas (TCGA) were analysed to identify miRNA-based signatures for LIHC prognosis with survival analysis and a semi-supervised principal components (SPC) method. A seven-miRNA signature was confirmed for overall survival (OS) prediction by comparing miRNA profiles in paired primary tumour and solid tumour normal tissues. Thereafter, a linear prognostic model that consisted of seven miRNAs was established and used to divide patients into high- and low-risk groups according to prognostic scores. Subsequent Kaplan-Meier analysis revealed that the seven-miRNA signature correlated with a good predictive clinical outcome for 5-year survival in LIHC patients. Additionally, this miRNA-based prognostic model could also be used for OS prognosis of LIHC patients in early stages, which could guide the future therapy of those patients and promote the OS rate. Moreover, the seven-miRNA signature was an independent prognostic factor. In conclusion, this signature may serve as a prognostic biomarker and guide LIHC therapy, and it could even be used as an LIHC therapeutic target in the future.
BibTeX
@inproceedings{fu2018novel,
  author = {Qiang Fu and Fan Yang and Tengxiao Xiang and Guoli Huai and Xingxing Yang and Liang Wei and Hongji Yang and Shaoping Deng},
  title = {{A novel microRNA signature predicts survival in liver hepatocellular carcinoma after hepatectomy}},
  booktitle = {Scientific},
  year = {2018},
  doi = {10.1038/s41598-018-26374-9},
}
Figure